Abstract
Objectives Removal of zero-COVID restrictions in China led to a surge in COVID-19 cases. In response, countries imposed restrictions on Chinese travelers. However, border policies may not provide substantial benefits and their assessment depends on accurate prevalence data.
Methods We analyzed quarantines and testing sufficient to prevent additional in-country transmission for February 13–19, 2023 based on World Health Organization (WHO) and self-reported infection rates to estimate prevalence.
Results Here we have shown that self-reported prevalence data indicated more stringent border restrictions compared to WHO-published prevalence statistics. No travel restrictions were required for Singapore for infections to not be greater than in complete border closure, while a 1-day quarantine, 2-day quarantine, and a 3-day quarantine were indicated for England, Germany, and Scotland respectively. A 10-day quarantine, 11-day quarantine, and 13-day quarantine were required for Italy, Japan, and France, respectively, to prevent an increase in the number of within-country infections due to travel, while South Korea required a complete border shutdown.
Conclusions Our results demonstrated the necessity for accurate and timely reporting of pandemic statistics to prevent an increase in viral spread. Through the minimum-quarantine analysis, countries can use science to determine policy, minimize international friction, and improve the cost-efficiency of interventions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding: This work was supported by the National Science Foundation of the United States of America (CCF 1918784 to Jeffrey P. Townsend).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
all of this data was openly available to the public before the initiation of the study and no additional data was obtained through requests, applications, or registrations; all data can be found here for the study: https://zenodo.org/records/8194600
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All raw data, documentation, sourcing, and analysis files can be accessed via Zenodo: https://zenodo.org/record/8194600
